Surgical & Medical Instruments & Apparatus · SIC 3841

AVITA Medical, Inc.

AVHHL

Watch

Latest revenue

$19.1M

as of 2026-03-31

Latest net income

$-10.6M

as of 2026-03-31

Net margin

-55.7%

as of 2026-03-31

6.4
of 10

ActaClear Score

Above avg
#54 of 138 in Surgical & Medical Instruments & Apparatus
new
Profitability·25%
5.2
Growth·15%
8.2
Value·20%
2.4
Quality·20%
9.9
Momentum·20%
7.2

Computed from 5 years of SEC fundamentals + latest market data, ranked within Surgical & Medical Instruments & Apparatus (138 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 6, 2026.

Community sentiment

Where do you think AVHHL is heading?

1 month
6 months
12 months
5 years
Sign in free to vote and see community sentiment

Price · 5Y

-6.4% / yr 26.1 pts / yr vs S&P 500 23.9% total
Compare:

Live market

delayed ≤15 min
$0.84
0.00%
Market cap
$26.0M
Enterprise value
$63.8M
P/E (trailing)
Forward P/E
P/B
Dividend yield
0.0%
52-wk high
$1.35
52-wk low
$0.56
Beta
Shares out
30.8M

5-year trend

What this company does

AI

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations The following discussion and analysis of AVITA Medical, Inc.’s (“AVITA Medical”, the “Company”), “we”, “our”, or “us”) financial condition and results of operations should be read in conjunction with our unaudited Consolidated Financial Statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q as well as the “Note Regarding Forward-Looking Statements” on page 3. Overview We are a leading therapeutic acute wound care company delivering transformative solutions. Our solutions improve the healing outcomes for patients with traumatic injuries and surgical repairs,…

AI summary unavailable — showing raw filing excerpt

Generated from AVHHL's filing dated 2026-05-14

Key risks

AI

Item 1A. RISK FACTORS In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed under Part I, Item 1A, “Risk Factors,” in the 2025 Annual Report and as updated from time to time in the Company’s subsequent Quarterly Reports on Form 10-Q. These factors could materially adversely affect our business, financial condition, liquidity, results of operations and capital position, and could cause our actual results to differ materially from our historical results or the results contemplated by the forward-looking statements contained in this Quarterly Report on Form 10-Q. There have been no material changes to the risk…

AI summary unavailable — showing raw filing excerpt

Generated from AVHHL's filing dated 2026-05-14

Profitability

Gross margin

82.1%

4.3%

Operating margin

-59.4%

32.6%

Net margin

-67.8%

29.5%

Return on equity

-1080.0%

756.6%

Return on assets

-86.2%

11.0%

Leverage

Debt / equity

11.53×

1745.8%

Long-term debt / equity

0.00×

100.0%

Debt / assets

92.0%

139.3%

Earnings tracker

QuarterRevenueYoYNet incomeYoYNet margin

Q1 2026

2026-03-31

$19.1M+4.0%$-10.6M+23.4%-55.7%

Q4 2025

2025-12-31

$18.2M-2.2%$-11.6M-0.3%-64.0%

Q3 2025

2025-09-30

$16.9M-12.9%$-13.2M+18.6%-78.0%

Q2 2025

2025-06-30

$18.2M+20.0%$-9.9M+35.6%-54.4%

Q1 2025

2025-03-31

$18.3M+65.0%$-13.9M+25.7%-75.6%

Q4 2024

2024-12-31

$18.6M$-11.6M-62.4%

Q3 2024

2024-09-30

$19.4M+42.1%$-16.2M-86.0%-83.6%

Q2 2024

2024-06-30

$15.2M+29.2%$-15.4M-48.2%-101.4%

Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.

Industry trend

Surgical & Medical Instruments & Apparatus · SIC 3841

No data yet for industry average

Your notes

Keep private notes on AVHHL — thesis, target price, catalysts to watch.

Visible only to you. Never shared. Never used to train AI.

Sign in to write a note

Insider activity

Insider buying

$151.7K

Insider selling

$0

Net activity

+$151.7K

Distinct insiders

2

Open-market trades over the last 365 days.

Recent transactions

DateInsiderTypeSharesPriceValue
2026-05-20

David D O'Toole

CFO

Purchase2,000$4.26$8.5K
2026-05-19

David D O'Toole

CFO

Purchase2,000$4.24$8.5K
2026-03-11

David D O'Toole

CFO

Purchase1,800$4.78$8.6K
2026-02-19

David D O'Toole

CFO

Purchase3,000$4.15$12.4K
2025-08-28

Robert Mcnamara

Director

Purchase10,000$4.50$45.0K
2025-08-26

David D O'Toole

CFO

Purchase2,000$4.52$9.0K
2025-08-19

Robert Mcnamara

Director

Purchase10,000$5.00$50.0K
2025-08-12

David D O'Toole

CFO

Purchase2,000$4.81$9.6K

Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.

Who owns AVHHL

No institutional holdings on file for AVHHL yet.

Source: SEC Form 13F-HR. Updated quarterly (45-day filing lag).

Top questions investors are asking

Coming once AVHHL's latest filing finishes processing.

Investor sentiment
No votes yet
0 this week · 0 total

Sign in to vote. Votes use 7-day half-life decay.

What matters about AVHHL?
Tap any that apply. Aggregates show what other investors flag.

Sign in to tap. 7-day half-life decay.

Latest filing impact
After reading, did this filing make you: